Tag: VEGF inhibitors

1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events ...

1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...

1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse events were mild-to-moderate ...